Overview
Multiply Labs and Retro Biosciences have partnered to tackle age-related diseases using state-of-the-art robotics. With this agreement, Multiply Labs will automate Retro’s manufacturing process to target the cellular drivers of aging. This collaboration marks the first commercial sale of Multiply Labs’ robotic system, which will support Retro’s efforts to develop life-changing therapies.
Key Benefits:
- Expedited transition: Automation helps Retro move faster from process development to clinical trials.
- Cost-efficient scale: Robotics reduce production costs, making therapies more affordable.
- Improved scalability: The modular structure of the robotics allows for easy scaling of manufacturing capabilities.
Unique Cell Therapies
Retro aims to bring unique cell therapies to patients. These therapies focus on age-related diseases and utilize advanced techniques in regenerative medicine. By leveraging Multiply Labs’ robotic systems, Retro can streamline the production of autologous and allogeneic therapies, particularly those involving mesenchymal stem cells, induced pluripotent stem cells, and human pluripotent stem cells.
Automation and Cell Therapy
Robotic systems are increasingly adopted in cell and gene therapy manufacturing to reduce costs and accelerate timelines. For instance, automation helps in:
- CAR-T therapy production
- Handling immune rejection challenges
- Streamlining autophagy processes in cell treatments
Partnerships and Manufacturing
Multiply Labs collaborates with various companies like Akron Bio, Charles River, Fedegari, and GenScript. These partnerships ensure that their robotic systems can operate market-leading GMP instruments, crucial for FDA-approved therapeutics manufacturing. The technology is designed for plug-and-play capabilities, reducing regulatory hurdles and speeding up automation timelines.
Impact on the Pharmaceutical Industry
Automation’s entry into the biotech field brings transformative changes. It enhances the capacity for individualized drugs and improves the scalability of cell therapy applications. Furthermore, robotic systems and automated manufacturing have become essential in creating efficient production lines, particularly for developing life-changing therapies.
In summary, this partnership signifies a major advancement in using robotics to make regenerative medicine and cell therapies more accessible and effective. By integrating advanced automated systems into their processes, Multiply Labs and Retro Biosciences are setting new benchmarks for the pharmaceutical industry.
